Outcomes of patients with acute prosthetic aortic valve endocarditis.


Journal

Asian cardiovascular & thoracic annals
ISSN: 1816-5370
Titre abrégé: Asian Cardiovasc Thorac Ann
Pays: England
ID NLM: 9503417

Informations de publication

Date de publication:
May 2021
Historique:
pubmed: 11 11 2020
medline: 25 11 2021
entrez: 10 11 2020
Statut: ppublish

Résumé

Prosthetic valve endocarditis is burdened by high mortality and morbidity. We reviewed our experience in the management of patients with acute prosthetic aortic valve infection and studied the implications and outcomes associated with surgical treatment and medical therapy. Data of 118 consecutive patients admitted during the period 2008-2018 with definite acute prosthetic aortic valve endocarditis, and presenting a surgical indication, were retrieved from the hospital database. Univariate and multivariate analysis were undertaken to study the association of preoperative characteristics with hospital mortality and the probability of undergoing a reoperation. Survival was assessed with Kaplan-Meier analysis. In the overall population, prosthesis dehiscence was independently associated with the possibility of undergoing surgical reoperation, while presentation with embolic stroke was associated with medical treatment. Hospital mortality was 24%, medical treatment was found to be independently associated with early death. One hundred (85%) patients underwent redo procedures; aortic valve replacement was performed in 53 and full root replacement in 47. Postoperative hospital mortality was 17%. Survival at 1-, 5-, and 8-years was 78%, 74%, and 66%, respectively. Freedom from reoperation and recurrent endocarditis was 95% at 8-year follow-up.Hospital mortality in patients who did not receive a redo operation was 61% with a survival rate of 17% at 1-year follow-up. Surgical mortality after reoperation for prosthetic aortic valve endocarditis is still high but mid-term outcomes are satisfactory. Failure to undertake surgery when indicated is an independent risk factor for early death.

Sections du résumé

BACKGROUND BACKGROUND
Prosthetic valve endocarditis is burdened by high mortality and morbidity. We reviewed our experience in the management of patients with acute prosthetic aortic valve infection and studied the implications and outcomes associated with surgical treatment and medical therapy.
METHODS METHODS
Data of 118 consecutive patients admitted during the period 2008-2018 with definite acute prosthetic aortic valve endocarditis, and presenting a surgical indication, were retrieved from the hospital database. Univariate and multivariate analysis were undertaken to study the association of preoperative characteristics with hospital mortality and the probability of undergoing a reoperation. Survival was assessed with Kaplan-Meier analysis.
RESULTS RESULTS
In the overall population, prosthesis dehiscence was independently associated with the possibility of undergoing surgical reoperation, while presentation with embolic stroke was associated with medical treatment. Hospital mortality was 24%, medical treatment was found to be independently associated with early death. One hundred (85%) patients underwent redo procedures; aortic valve replacement was performed in 53 and full root replacement in 47. Postoperative hospital mortality was 17%. Survival at 1-, 5-, and 8-years was 78%, 74%, and 66%, respectively. Freedom from reoperation and recurrent endocarditis was 95% at 8-year follow-up.Hospital mortality in patients who did not receive a redo operation was 61% with a survival rate of 17% at 1-year follow-up.
CONCLUSIONS CONCLUSIONS
Surgical mortality after reoperation for prosthetic aortic valve endocarditis is still high but mid-term outcomes are satisfactory. Failure to undertake surgery when indicated is an independent risk factor for early death.

Identifiants

pubmed: 33167670
doi: 10.1177/0218492320974112
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

268-277

Auteurs

Pietro Giorgio Malvindi (PG)

Wessex Cardiothoracic Centre, University Hospital Southampton, Southampton, UK.

Carlo Olevano (C)

Wessex Cardiothoracic Centre, University Hospital Southampton, Southampton, UK.

Suvitesh Luthra (S)

Wessex Cardiothoracic Centre, University Hospital Southampton, Southampton, UK.

Geoffrey Tsang (G)

Wessex Cardiothoracic Centre, University Hospital Southampton, Southampton, UK.

Clifford Barlow (C)

Wessex Cardiothoracic Centre, University Hospital Southampton, Southampton, UK.

Sunil Ohri (S)

Wessex Cardiothoracic Centre, University Hospital Southampton, Southampton, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH